Special Issue "Targeting Hedgehog Signaling in Cancer"
Deadline for manuscript submissions: 31 October 2018
The number of Hedgehog pathway publications about cancer is constantly increasing, but together with this increase, the confusion about the efficacy of targeted therapies also increases. In part, the problem is the need to identify the cancer types/subtypes that truly depend on Hedgehog signalling for proliferation, and the molecular mechanisms of that dependency, which range from mutations in Patched1 or Smoothened, upregulation of Hedgehog ligands, amplification of Gli1 or Gli2, or crosstalk with other signalling pathways that increase Gli activation.
The scope of this Special Issue is to generate a comprehensive and curated view of the types of Hedgehog-dependent cancers, the origin of that dependency, the most rational molecular targets for therapy, and the results of past or current clinical trials. The issue will review the use of Vismodegib, Sonidegib, and the other Smoothened inhibitors currently awaiting approval, the use of arsenic compounds, itraconazole, and animal experimentation with Gli inhibitors such as GANT61. It will also discuss the findings of studies supplementing vitamin D, a purported Smoothened inhibitor, and the impact of Statins use for the control of cardiovascular disease on the risk of developing Hedgehog dependent cancers. Furthermore, discussion of the alternative mechanisms of resistance to Smoothened inhibitors, as well as potential solutions, will be presented.
We look forward to your valuable contributions.
Dr. Natalia Riobo-Del Galdo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Smoothened inhibitors
- Non-canonical activation of Gli
- Efficacy and safety
- Mechanisms of treatment resistance